Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses targeting the androgen receptor in breast cancer.
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses targeting the androgen receptor in breast cancer.
The androgen receptor is a nice target, Fuqua says, because it is frequently expressed in breast cancer, and several drugs that target it are already available for other tumor types.
In the past year, genomic work has revealed that breast cancer is an extremely heterogenous disease, with several infrequently-expressed targets. Fuqua says that treatment may have to be tailor-made for each patient because of these low levels of expression based on heterogeneity.
Fuqua says that because of the frequency of expression and the availability of drugs, the oncology community will learn how to apply the knowledge and utility of the androgen receptor to the treatment of breast cancer.
Sacituzumab Govitecan/Pembrolizumab in HR+ Breast Cancer Show Nonsignificant PFS Increase
June 2nd 2024Progression-free survival was numerically improved with pembrolizumab plus sacituzumab govitecan vs sacituzumab govitecan alone in patients with HR-positive, HER2-negative metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Ruxolitinib Offers Durable Hematocrit Control, Low Thrombosis Risk in PV
May 30th 2024In an interview with Targeted Oncology, Aleksander L. Chojecki, MD, discussed findings from his research on hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib.
Read More